Rationale and Study Design for One-Stop Assessment of Renal Artery Stenosis and Renal Microvascular Perfusion with Contrast-Enhanced Ultrasound for Patients with Suspected Renovascular Hypertension
Renal artery stenosis (RAS) is a significant medical condition often associated with renovascular hypertension and chronic kidney disease (CKD). It is particularly prevalent among older individuals, where atherosclerosis accounts for nearly 90% of cases, typically affecting the ostium and proximal third of the main renal artery. RAS is not only a vascular issue but also closely linked to abnormalities in renal microvascular perfusion (RMP), which can lead to renal dysfunction and cardiovascular complications. Despite the critical need for accurate diagnosis and management, conventional imaging techniques have limitations in simultaneously assessing RAS and RMP. This study aims to evaluate the feasibility, safety, and accuracy of contrast-enhanced ultrasound (CEUS) as a one-stop diagnostic tool for both RAS and RMP in patients with suspected renovascular hypertension.
Background and Rationale
RAS is a condition with a poor prognosis, often leading to severe complications such as renal dysfunction, cardiovascular events, and mortality. The association between RAS and RMP abnormalities is well-documented, with renal cortical perfusion dysfunction becoming significant even at a stenosis level of around 30%. Patients with hypertension and low-grade RAS experience a faster decline in renal function and a higher risk of cardiovascular complications compared to those with patent renal arteries. Therefore, a comprehensive evaluation of both RAS and RMP is crucial for effective management of renovascular hypertension.
Conventional imaging techniques, such as computed tomography angiography (CTA) and magnetic resonance angiography (MRA), are commonly used to assess RAS. However, these methods often require the use of contrast agents, which can be hazardous for patients with renal insufficiency, particularly those with advanced CKD. Additionally, radionuclide imaging, another diagnostic tool, involves exposure to radioactivity, further limiting its applicability. CEUS, on the other hand, is a non-invasive and safe imaging method that uses microbubble-based contrast agents, making it suitable for patients with renal impairment. CEUS has been shown to be effective in evaluating both RAS and RMP, but there is a lack of comprehensive studies on its application in patients with renovascular hypertension.
Study Design and Methods
This study is designed as a single-center diagnostic trial with a sample size of 440 patients. The primary objective is to evaluate the feasibility and accuracy of CEUS in diagnosing RAS and assessing RMP in patients with suspected renovascular hypertension. The study will include adult patients (aged 18 years or older) with CKD stages 1–3 and suspected resistant hypertension. Exclusion criteria include severe heart or pulmonary dysfunction, sensitivity to contrast agents, pregnancy, coexisting cancer, and poor imaging quality.
Participants will undergo CEUS, CTA, and radionuclide imaging. CEUS will be performed using a high-resolution ultrasonograph (GE LOGIQ E8 with a 3.5–5 MHz electronic probe) and an intravenous contrast agent (SonoVue, Bracco, Milan, Italy). The contrast agent will be administered as a bolus injection, and RAS will be diagnosed based on indirect and direct criteria. RMP variables, including peak intensity (PI), time-to-peak intensity (TTP), mean transit time (MTT), and area under the curve (AUC), will be analyzed using specialized software (Sonoliver®, TomTec Imaging Systems, Germany).
The diagnostic value of CEUS for RAS will be compared with CTA, focusing on low-grade (lumen reduced by <60%) and high-grade (lumen reduced by ≥60%) stenosis. The accuracy, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and area under the receiver operating characteristic (ROC) curve will be assessed. Additionally, the association between CEUS findings for RMP and glomerular filtration rate (GFR) measured by radionuclide imaging will be analyzed using Pearson correlation analysis.
Study Outcomes
The primary outcome of this study is the diagnostic accuracy of CEUS compared to CTA in identifying low-grade and high-grade RAS. The secondary outcome is the correlation between CEUS-derived RMP variables and GFR. Safety endpoints include the incidence of adverse events related to the imaging methods, such as allergic reactions, palpitations, dizziness, and contrast-induced nephropathy (CIN). CIN will be diagnosed based on specific criteria, including an increase in serum creatinine concentration within 48–72 hours after contrast administration.
Statistical Analysis
The study is powered to detect significant differences in diagnostic accuracy between CEUS and CTA. The sample size of 440 was calculated based on an assumed sensitivity of 0.85 and specificity of 0.9, with an acceptable variation of 0.05 for both parameters. Statistical analysis will be performed using STATA 14.0 software, with continuous variables expressed as mean ± standard deviation (SD) and categorical variables as frequencies or percentages. The diagnostic value of CEUS will be assessed using ROC curve analysis, and the correlation between RMP variables and GFR will be evaluated using Pearson correlation analysis.
Discussion
This study aims to address the limitations of current imaging techniques by evaluating the feasibility of CEUS as a one-stop diagnostic tool for RAS and RMP in patients with suspected renovascular hypertension. CEUS offers several advantages, including its non-invasive nature, safety in patients with renal insufficiency, and ability to provide real-time, quantitative estimates of RMP. The study will provide valuable insights into the diagnostic accuracy of CEUS for RAS, particularly in patients with low-grade stenosis, and its potential role in assessing RMP.
The findings of this study could have significant clinical implications. CEUS may serve as a valuable tool for guiding patient selection and evaluating the efficacy of interventions such as angioplasty and stenting. Additionally, the study will contribute to the establishment of standardized parameters for assessing RMP, which is currently lacking in the literature. By providing a safe and effective imaging method for patients with renal impairment, CEUS has the potential to improve the management of renovascular hypertension and reduce the risk of associated complications.
Study Limitations
Despite its potential benefits, this study has several limitations. First, it is a single-center study, which may limit the generalizability of the findings to broader populations. Second, the observational nature of the study introduces the possibility of unmeasured confounding factors. Third, the lack of international standards for assessing RMP and the variability in CEUS parameters across different patient groups may affect the interpretation of the results. Fourth, CEUS is operator-dependent, and the quality of imaging may vary based on the experience of the radiologist. Finally, the inherent variability of CEUS, influenced by factors such as patient characteristics, contrast agent used, and machine settings, may impact the reproducibility of the results.
Conclusion
In summary, this study is designed to evaluate the feasibility, safety, and accuracy of CEUS as a one-stop diagnostic tool for RAS and RMP in patients with suspected renovascular hypertension. By addressing the limitations of conventional imaging techniques, CEUS has the potential to provide a comprehensive and non-invasive method for assessing both RAS and RMP, particularly in patients with renal insufficiency. The findings of this study will contribute to the expanding clinical applications of CEUS and improve the management of renovascular hypertension.
doi.org/10.1097/CM9.0000000000000002
Was this helpful?
0 / 0